Grant Sean's Form 4 filing
Vera Therapeutics, Inc. (VERA) · filed Feb 8, 2023
- Accession no.
- 0001209191-23-007769
- Filed
- Feb 8, 2023
- Trade date
- Feb 6, 2022
- Filing delay
- 367 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $100.0K. It was filed 367 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0001209191-23-010583 (Feb 17, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grant SeanCIK 0001872792 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2022 | Class A Common Stock | PPurchaseAcquired | +14,285 | $7.00 | +$99,995 | 49,933 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.